

MEDICAL POLICY STATEMENT

Ohio Medicaid

Policy Name & Number	Date Effective
Tumor Treatment Field Devices for Glioblastoma Multiforme OH MCD-MM-1224	11/01/2022-02/28/2023
Policy Type	
MEDICAL	

Table of Contents

A. Subject.....	2
B. Background.....	2
C. Definitions	2
D. Policy	3
E.	

A. Subject

Tumor Treatment Field Devices for Glioblastoma Multiforme (GBM)

B. Background

Glioblastoma Multiforme is the most common central nervous system malignancy of the brain in adults, with an average onset (an a)10.6 (v)-2.1 8.9 (,)-6.6 (w)2.6 1 8.9 (,Td[14 17.6 (.921 -29

Archived

H. References

1. Batchelor T., (2019, November). Initial Treatment and prognosis of newly diagnosed glioblastoma in adults. Retrieved from UpToDate on June 28, 2022.
2. Chukwueke U, Wen P, (2019, March). Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. Retrieved from CNS Oncology on June 28, 2022.
3. Fernandes, Catarina, (2017, September). Current Standards of Care in Glioblastoma Therapy. Retrieved from www.ncbi.nih.gov on June 28, 2022
4. Food and Drug Administration. .6 5 S6 (s)-2 a6 (s)-2 usTd[()]-6 (20)10.1 2022 (m)-6

Archived